8-K: Cognition Therapeutics Announces Positive Topline Results from Phase 2 SHIMMER Study in Dementia with Lewy Bodies

Cognition Therapeutics' Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies showed significant positive signals across multiple symptom domains.

Summary

• Cognition Therapeutics has released topline data from its Phase 2 SHIMMER study, which evaluated CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB).
• The study, partially funded by a $30 million grant from the National Institute on Aging (NIA), enrolled 130 participants across 31 sites in the U.S.
• Participants were randomized to receive either 100mg or 300mg of CT1812 or a placebo daily for six months.
• The study assessed safety, tolerability, and impact on behavior, cognition, function, and motor skills.
• Results showed that CT1812 demonstrated significant slowing of disease progression across multiple domains compared to placebo.
• Specifically, there was an 82% slowing in neuropsychiatric symptoms, a 114% slowing in caregiver distress, up to 91% slowing of cognitive decline, a 52% preservation in activities of daily living, and a 62% preservation in motor function.
• The safety profile of CT1812 was consistent with previous trials, with most adverse events being mild or moderate.

Sentiment

Score: 8

Explanation: The document presents very positive results from a Phase 2 trial, with strong efficacy signals and a manageable safety profile. This suggests a promising outlook for the drug's development, although further trials are needed.

Positives

• CT1812 showed significant positive impact on neuropsychiatric symptoms, cognitive decline, daily living activities, and motor function.
• The study demonstrated a favorable safety and tolerability profile for CT1812, consistent with previous trials.
• The results suggest that CT1812 has the potential to change the course of disease for patients with dementia with Lewy bodies.
• The study was conducted in collaboration with Lewy Body Dementia Association (LBDA) Centers of Excellence, academic centers, and industry partners.
• The treatment differences between CT1812 and placebo increased over the 6-month study period.

Negatives

• Some participants experienced treatment-emergent adverse events (TEAEs), with the most common being falls, headaches, and lipase increase.
• A small number of participants experienced serious adverse events (SAEs), including one related to the study drug (metabolic encephalopathy).
• There were some discontinuations due to adverse events, with a higher rate in the 300mg CT1812 group.
• There were 3 deaths during the study, but they were not considered treatment related.
• Some participants experienced elevations in liver function tests (LFTs), with 3x ULN (AST or ALT) in 7% of the CT1812 group.

Risks

• The study results are from a Phase 2 trial and need to be confirmed in larger Phase 3 trials.
• The long-term efficacy and safety of CT1812 are still unknown.
• Regulatory approval is not guaranteed, and the timeline for approval is uncertain.
• The company faces competition from other companies developing treatments for dementia with Lewy bodies.
• The company's ability to secure new funding and manage growth is a risk factor.

Future Outlook

The company plans to present the data at the ILBDC in January 2025, convene advisors for protocol input, engage with regulatory experts, conduct commercial research, and prepare for end-of-Phase 2 meetings.

Management Comments

• The company believes the data provide support for advancement of CT1812 as a treatment for dementia with Lewy bodies.
• The company is grateful to everyone involved in the COG1201 SHIMMER Trial.

Industry Context

Dementia with Lewy bodies is the second most common cause of dementia after Alzheimer's disease, and there is a significant unmet need for effective treatments. The positive results from this study could position Cognition Therapeutics as a key player in this space.

Comparison to Industry Standards

• The study's focus on multiple symptom domains (behavior, cognition, function, and movement) aligns with the complex nature of DLB, which is often a challenge for drug development.
• The reported 82% slowing of neuropsychiatric symptoms is a significant result compared to other treatments in development for DLB.
• The 114% slowing of caregiver distress is a notable outcome, as caregiver burden is a major concern in DLB.
• The study's use of multiple cognitive assessments (MoCA, CDR, CAF) provides a comprehensive view of cognitive function, which is important for DLB.
• The 52% preservation in activities of daily living and 62% preservation in motor function are also clinically meaningful outcomes.

Stakeholder Impact

• Shareholders may react positively to the strong clinical results.
• Patients with DLB and their families may have increased hope for a new treatment option.
• Employees of Cognition Therapeutics may be motivated by the positive study outcomes.
• The results may attract potential partners and investors.

Next Steps

• Podium presentation at ILBDC in January 2025.
• Convene advisors to provide protocol input.
• Engage with regulatory experts.
• Conduct commercial research.
• Prepare for end-of-Phase 2 meetings.

Key Dates

Keywords

Dementia with Lewy Bodies, CT1812, Cognition Therapeutics, Clinical Trial, Neuropsychiatric Symptoms, Cognitive Decline, Motor Function, Phase 2 Study, SHIMMER, Lewy Body Dementia